Loading...
•
Sep 30, 2022
Scynexis Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022.
Key Takeaways
SCYNEXIS reported Q3 2022 financial results, with a focus on refocusing resources on the clinical development of ibrexafungerp for severe, hospital-based indications. BREXAFEMME net revenues were $1.6 million in Q3 2022, representing a 13% increase over Q2 2022. The company ended the quarter with $96.1 million in cash, cash equivalents, and short-term investments, projecting a cash runway into Q2 2024.
Refocusing its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.
Ivor Macleod joined SCYNEXIS as Chief Financial Officer.
BREXAFEMME prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million.
SCYNEXIS ended the third quarter with a cash, cash equivalents and short-term investment balance of $96.1 million and has a projected cash runway into Q2 2024.
Scynexis
Scynexis
Forward Guidance
SCYNEXIS believes that its existing cash, cash equivalents and short-term investments will enable the Company to fund its operating requirements into Q2 2024.